Mitochondrial replacement (MR) serves as a crucial test case and learning guide for the scientific, ethical, and regulatory challenges of future reproductive breakthroughs. The lessons learned from the regulatory review process of MR over the last decade promise to enrich the emerging dialog over genome editing.
Concerns over the prospect of germline modification of the human genome have recently been heightened by dramatic advances in genome editing technology and by a widely publicized attempt to edit the genome of non-viable human zygotes (Jinek et al., 2012; Liang et al., 2015) . These well-placed concerns have reignited the debate on the very notion of human germline gene therapy in general and germline genome editing in particular. What is more, these concerns have given rise to a structured discourse on the ''scientific, medical, and ethical considerations'' of human gene editing under the leadership of the US National Academies of Sciences, Engineering, and Medicine.
Often lost in the conversation, however, is the fact that human germline perturbation via mitochondrial replacement (MR) has recently been reviewed and approved by the UK Parliament. The first example of state-sanctioned germline gene therapy in the human, MR is designed to prevent, if not eliminate, diseases attributable to mutations in mitochondrial DNA (mtDNA) . Consequential in its germline impact and groundbreaking in its regulatory evaluation process, the experience gained in the vetting of MR could and should inform the current genome editing debate. In this Commentary, we discuss the nature and significance of MR, describe its recent approval process, review its germline implications, and explore its potential to instruct science policy makers on the challenges posed by human genome editing.
Mitochondrial Genome Replacement Therapy
Mutant mtDNA gives rise to highly debilitating and frequently fatal inborn errors of energy metabolism. Cure for those affected remains elusive. What is more, the non-Mendelian nature of mitochondrial genetics diminishes the utility of preimplantation genetic diagnosis. This dismal state of affairs may be reversed before too long. On February 3, 2015, the UK House of Commons voted to approve the substitution of mutant oocytic or zygotic mtDNA with a donated wild-type counterpart through maternal spindle transfer (MST) or pronuclear transfer (PNT), respectively. The House of Lords followed suit shortly thereafter. Implementation of these MR variants now rests with the Human Fertilization and Embryology Authority (HFEA) in its role as the regulator of fertility clinics and of human embryo research. HFEAapproved clinical trials of MR could commence as early as this year. The first post-procedural birth could follow suit before too long. As such, MR serves as a crucial test case and learning guide for the scientific, ethical, and regulatory challenges of future reproductive breakthroughs. It is in this context that some of the lessons learned over the last decade could potentially enrich the emerging dialog over genome editing.
Going Germline: The Mitochondrial Barrier Among the leading concerns raised by the prospect of editing the human genome, the notion of crossing the germline barrier has featured prominently. However, should editing of the human genome ever come to pass, it is unlikely to constitute the first therapeutic intervention to breach the germline barrier. This outcome is more likely to follow HFEA-approved clinical trials of MR, the ability of which to establish near complete homoplasmy of heterologous (donor) mtDNA in the human zygote has now been repeatedly documented (Craven et al., 2010; Tachibana et al., 2013; Paull et al., 2013) . Similar observations were made for the resultant blastocysts and their derivative embryonic stem cells (Craven et al., 2010; Tachibana et al., 2013; Paull et al., 2013) . Furthermore, the application of MST in non-human primates has been shown to support normal fertilization, as well as embryonic and fetal development, culminating in the birth of apparently healthy offspring (Tachibana et al., 2009 ). These offspring, now approaching the 10 year mark, have been reported to display virtual somatic and germline homoplasmy traceable to the donor mtDNA. Placed in historical perspective, MR follows earlier attempts at germline modification-that is, the empirical transfer of donor ooplasm into the oocytes of patients experiencing repeated intractable implantation failure (Cohen et al., 1997) . Of the 35 patients so treated since 1997, 14 have given birth to apparently healthy infants replete with clear-cut representation of the donor mtDNA.
The once-prevalent notion that the mitochondrial germline barrier is of lesser consequence than its nuclear counterpart is undergoing revision. In part, former convictions have been predicated on the erroneous assumption that mitochondrial function is limited to oxidative phosphorylation. However, evidence now implicates the mitochondrial genome in functions as diverse as apoptosis, calcium homeostasis, steroidogenesis, and innate immunity to name a few. Former convictions may have also been rooted in the presumption that a mitochondrial germline breach is without effect on its nuclear counterpart. This view, however, overlooks the fact that the two obligate, if size-discrepant cellular genomes are highly interactive. Indeed, the mitochondrial genome may well be viewed as an indispensable extension of its nuclear counterpart from which it is physically, but not functionally, distinct. Not surprisingly, this inter-dependence has proven of special relevance to MR wherein novel nucleocytoplasmic hybrids might affect allelic inter-genomic (including epigenetic) interactions (Reinhardt et al., 2013) . The latter contention, broadly documented in model organisms, has also been borne out in the human wherein mismatched mito-nuclear allelic combinations appear to have impacted mutant phenotypic expression. All told, these observations are consonant with the view that the likely epistasis associated with mitochondrial germline modification may alter the functionality of allelic nuclear partners in a heritable fashion. Following this line of reasoning to its logical conclusion might suggest that the ''essence of being human'' need not be viewed as the sole domain of the nuclear genome, the very functionality of which is highly dependent on finely tuned mito-nuclear interactions.
The Genome Editing Challenge: Inferences from Mitochondrial Replacement By many measures, the notion of germline editing of the human genome is just as consequential as replacing mutant mitochondrial genes, not to mention the total cognate allelic mix. Both must contend with breaching the germline barrier. Both entail the manipulation of a human embryo. Both must address significant safety concerns. Both must engage a skeptical public. Both must face up to the first-inhuman imponderable. Both must grapple with ethical concerns. Both must stamp out unease with technology running unchecked. And both must assuage fears of an altered natural order known to man for millennia. It follows that key insights derived from the MR experience may well prove applicable and potentially helpful to deliberating the genome editing challenge. Against this backdrop, we offer five select science policy elements for further consideration: the presence of a compelling medical rationale, the safety and efficacy of the preclinical science, the rigor of the ethical framework, the scope of the public engagement, and the soundness of the regulatory constructs (Table 1) .
As with any medical intervention, a compelling necessity must feature front and center. This element was very much in evidence in the case of mitochondrial DNA diseases for which neither cure nor reliable prenatal risk stratification were available. If therapeutic editing of the human genome is to be permitted, a similarly weighty medical imperative must applythat is, the prevention of disorders for which cure is non-existent and preimplantation genetic diagnosis is unavailing. Uniparental homozygosity for dominant monogenic disorders (e.g., Huntington's disease) or biparental homozygosity for recessive monogenic disorders (e.g., deafness or sickle-cell disease) might constitute appropriate initial targets. Editing of the mitochondrial (or nuclear) genome with an eye toward preventing mitochondrial DNA diseases may also be considered. Redress of heritable forms of infertility through the editing of the genome of patient-specific iPSC-derived gametes might constitute a more distant goal. By contrast, venturing into risk reduction of ill-understood polygenic diseases would be ill advised. It follows that MR and therapeutic editing of the human genome are best viewed at present as highly limited in scope-that is, as niche applications the target populations of which are highly circumscribed. A recent report estimates that no more than an average of 778 births per year of US women at risk (< 0.02% of total births) stand to benefit from the implementation of MR (Gorman et al., 2015) . A key variable associated with the approval of MR by the UK Parliament was the uncompromising focus of the HFEA on the safety and efficacy of the preclinical science. As summarized by acknowledged experts in three separate public reports and expounded upon in multiple public testimonials, MR was deemed safe and ''potentially useful for a specific and defined group of patients whose offspring may have severe or lethal genetic disease'' (Human Fertilisation and Embryology Authority, 2014). Excellence, fastidiousness, and transparency won the day, the first-in-human imponderable notwithstanding. The prospect of germline editing of the human genome has yet to be subjected to such scrutiny. A recent attempt at editing the genome of human zygotes revealed the technology to be a work in progress (Liang et al., 2015) . Incomplete and inaccurate targeting, let alone mosaicism and off-target effects, remains to be addressed among other lingering challenges (Liang et al., 2015) . Absent resolution of these shortcomings, germline modification of the human genome must not proceed. Instead, redoubling of efforts at the level of the non-human primate appears especially well advised (Niu et al., 2014) . At some point, however, the first-in-human step will have to be broached. Determining when and if to take this step remains a difficult task, even in the face of a favorable risk-benefit ratio. Still, thorough, interdisciplinary, and publicly transparent evaluation of the preclinical data by a community of content experts will go a long way toward facilitating this trying assignment. A case in point is the Consensus Study of the National Academy of Medicine (Scientific, Medical, and Ethical Considerations of Human Gene Editing) , which is presently underway.
Yet another central element in the affirmation of MR was the rigor of the ethical framework. Hardly an afterthought, the ethics of MR was the subject of a 6 month inquiry by a working group of the Nuffield Council on Bioethics (Nuffield Council on Bioethics, 2012). An independent body, the Nuffield Council focused on the identity, rights, and parentage of the prospective non-consenting children and on the societal fallout thereof only to conclude that ''it would be ethical for families to use these techniques as treatment'' (Nuffield Council on Bioethics, 2012). The resultant publicly available report remains an important resource (Nuffield Council on Bioethics, 2012). Ethical issues were also the focus of lengthy parliamentary debates during which the airing of secular and religious points of view were afforded equal shrift. The prospect of therapeutic editing of the human genome deserves an equally thorough and independent ethical review. This task could be accomplished in part or in whole by the unfolding initiative of the National Academy of Medicine. Additionally, this role could be assumed by other eminently qualified entities such as the Presidential Commission for the Study of Bioethical Issues or The Hastings Center.
In a move designed to take the pulse of the citizenry, the regulatory evaluation process of MR incorporated an extensive public consultation process. Cognizant of the import of the moment, the UK government resolved to seek the ''public views on emerging techniques designed to prevent mitochondrial DNA disease'' (Human Fertilisation and Embryology Authority, 2013) . Three public workshops, 1,000 face-to-face interviews, 1,836 responses to questionnaires, 2 public meetings, and a focus group followed suit (Human Fertilisation and Embryology Authority, 2013) . In reporting its findings, the HFEA concluded that ''there is general support for permitting mitochondria replacement in the UK, so long as it is safe enough to offer in a treatment setting and is done so within a regulatory framework'' (Human Fertilisation and Embryology Authority, 2013). The HFEA further offered that, ''despite the strong ethical concerns that some respondents to the consultation expressed, the overall view is that ethical concerns are outweighed by the arguments in favour of permitting mitochondria replacement'' (Human Fertilisation and Embryology Authority, 2013 ). An equally extensive public engagement process replete with government, religious, civic, and scientific leaders will be required for the possibility of germline editing of the human genome. It is difficult to envision a transition of this magnitude absent a measure of the public outlook. Failure to engage in extensive and inclusive deliberations in search of the plurality of opinion is not an option.
Finally, note must be made of the rigorous regulatory evaluation process of MR through the combined efforts of the HFEA and the UK Parliament. Quintessentially British, this paradigm is hardly importable. It follows that the regulatory evaluation of therapeutic genome editing in the United States will draw on extant constructs. Regrettably, this process stands to be deprived of the all-important input of the Recombinant DNA Advisory Committee (RAC) of the NIH (National Institutes of Health, 2015) . A highly regarded open review forum of publicly funded gene therapy trials, the RAC will not entertain proposals to edit the genome of the human embryo in compliance with current policy and with the Dickey-Wicker Amendment (National Institutes of Health, 2015). Whether or not the regulatory process will be well served by the inclusion of a RAC alternative appears worthy of further consideration. As the MR approval process has plainly shown, there is no substitute to the input of independent content experts (Human Fertilisation and Embryology Authority, 2014). Absent such input, oversight of preclinical scientific research protocols will remain the domain of Institutional Review Boards and Institutional Biosafety Committees. Translational oversight will be exercised by the FDA wherein the Office of Cellular, Tissue, and Gene Therapies oversees ''human cells used in therapy involving the transfer of genetic material by means other than the union of gamete nuclei.''
The debate over germline gene transfer has been unfolding for over half a century, ever since the emergence of recombinant ''genetic engineering.'' What is different this time around is the realization that genome editing has come of age and that its implementation is no longer a mere theoretical possibility. Applying the principles relied upon in the regulatory evaluation of MR will go a long way toward assuring that the prospect of therapeutic genome editing in the human is the subject of a thorough, inclusive, ethical, safety-minded, and confidenceinspiring process.
